15
Views
81
CrossRef citations to date
0
Altmetric
Cell Growth and Development

Rat Protein Tyrosine Phosphatase η Suppresses the Neoplastic Phenotype of Retrovirally Transformed Thyroid Cells through the Stabilization of p27Kip1

, , , , , , , , & show all
Pages 9236-9246 | Received 15 Mar 2000, Accepted 27 Sep 2000, Published online: 28 Mar 2023
 

Abstract

The r-PTPη gene encodes a rat receptor-type protein tyrosine phosphatase whose expression is negatively regulated by neoplastic cell transformation. Here we first demonstrate a dramatic reduction in DEP-1/HPTPη (the human homolog of r-PTPη) expression in a panel of human thyroid carcinomas. Subsequently, we show that the reexpression of the r-PTPη gene in highly malignant rat thyroid cells transformed by retroviruses carrying the v-mos and v-ras-Kioncogenes suppresses their malignant phenotype. Cell cycle analysis demonstrated that r-PTPη caused G1 growth arrest and increased the cyclin-dependent kinase inhibitor p27Kip1protein level by reducing the proteasome-dependent degradation rate. We propose that the r-PTPη tumor suppressor activity is mediated by p27Kip1 protein stabilization, because suppression of p27Kip1 protein synthesis using p27-specific antisense oligonucleotides blocked the growth-inhibitory effect induced by r-PTPη. Furthermore, we provide evidence that in v-mos-or v-ras-Ki-transformed thyroid cells, the p27Kip1 protein level was regulated by the mitogen-activated protein (MAP) kinase pathway and that r-PTPη regulated p27Kip1 stability by preventing v-mos- or v-ras-Ki-induced MAP kinase activation.

View retraction statement:
Retraction for Trapasso et al., “Rat Protein Tyrosine Phosphatase η Suppresses the Neoplastic Phenotype of Retrovirally Transformed Thyroid Cells through the Stabilization of p27Kip1”

ACKNOWLEDGMENTS

This work was supported by grants from AIRC (Progetto Speciale Oncosoppressori), from the Progetto Finalizzato Biotecnologie of the CNR, the MURST projects Terapie antineoplastiche innovative and Piani di Potenziamento della Rete Scientifica e Tecnologica, and from the Ministero della Sanità. We thank the Associazione Partenopea per la Ricerche Oncologiche (APRO) for its support. Francesco Trapasso, Paola Bruni, Angelo Boccia, Gustavo Baldassarre, and Antonella Stella were recipients of a fellowship from the Fondazione Italiana per la Ricerca sul Cancro (FIRC).

We are grateful to Jean Gilder for editing the text.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.